{"entity":{"type":"insider","cik":"0001384243","url":"/insider/0001384243","json_url":"/insider/0001384243.json","name":"Quart Barry D","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":38,"n_filings":26,"first":"2009-05-21","last":"2026-04-29","span_basis":"filed_date"},"name_variants":[{"name":"Quart Barry D","source":"filing","n_filings":26,"first_seen":"2009-05-21","last_seen":"2026-04-29"}],"transactions":[{"id":5979548,"accession":"0001384243-26-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001384243-26-000010","line_url":"/filing/0001384243-26-000010#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13099.0,"shares_display":"13,099","price_per_share":50.1,"price_display":"50.10","price_state":"stated","total_value":656259.9,"total_display":"656,259.90","total_whole":"656,260","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-28","filed_date":"2026-04-29","scope":"insider"},{"id":5861536,"accession":"0001384243-26-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001384243-26-000008","line_url":"/filing/0001384243-26-000008#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6901.0,"shares_display":"6,901","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":345050.0,"total_display":"345,050.00","total_whole":"345,050","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-06","filed_date":"2026-04-08","scope":"insider"},{"id":5898344,"accession":"0001384243-26-000004","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001384243-26-000004","line_url":"/filing/0001384243-26-000004#line-4","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2690.0,"shares_display":"2,690","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":121050.0,"total_display":"121,050.00","total_whole":"121,050","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-12","filed_date":"2026-02-12","scope":"insider"},{"id":5898340,"accession":"0001384243-26-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001384243-26-000004","line_url":"/filing/0001384243-26-000004#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":110.0,"shares_display":"110","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":4950.0,"total_display":"4,950.00","total_whole":"4,950","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-10","filed_date":"2026-02-12","scope":"insider"},{"id":5946070,"accession":"0001384243-26-000002","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001384243-26-000002","line_url":"/filing/0001384243-26-000002#line-6","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2602.0,"shares_display":"2,602","price_per_share":45.02,"price_display":"45.02","price_state":"stated","total_value":117142.04,"total_display":"117,142.04","total_whole":"117,142","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-04","scope":"insider"},{"id":5946066,"accession":"0001384243-26-000002","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001384243-26-000002","line_url":"/filing/0001384243-26-000002#line-4","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12528.0,"shares_display":"12,528","price_per_share":45.27,"price_display":"45.27","price_state":"stated","total_value":567142.56,"total_display":"567,142.56","total_whole":"567,143","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-04","scope":"insider"},{"id":5946063,"accession":"0001384243-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001384243-26-000002","line_url":"/filing/0001384243-26-000002#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":830.0,"shares_display":"830","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":37350.0,"total_display":"37,350.00","total_whole":"37,350","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider"},{"id":4050074,"accession":"0001384243-25-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001384243-25-000004","line_url":"/filing/0001384243-25-000004#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20129.0,"shares_display":"20,129","price_per_share":41.51,"price_display":"41.51","price_state":"stated","total_value":835554.79,"total_display":"835,554.79","total_whole":"835,555","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-15","filed_date":"2025-12-17","scope":"insider"},{"id":4036517,"accession":"0001415889-25-016724","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-25-016724","line_url":"/filing/0001415889-25-016724#line-6","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12336.0,"shares_display":"12,336","price_per_share":30.39,"price_display":"30.39","price_state":"stated","total_value":374891.04,"total_display":"374,891.04","total_whole":"374,891","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-11","filed_date":"2025-06-11","scope":"insider"},{"id":4036514,"accession":"0001415889-25-016724","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-016724","line_url":"/filing/0001415889-25-016724#line-4","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8212.0,"shares_display":"8,212","price_per_share":30.36,"price_display":"30.36","price_state":"stated","total_value":249316.32,"total_display":"249,316.32","total_whole":"249,316","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-11","scope":"insider"},{"id":4036510,"accession":"0001415889-25-016724","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-016724","line_url":"/filing/0001415889-25-016724#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals International, plc","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Ordinary Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6900.0,"shares_display":"6,900","price_per_share":30.26,"price_display":"30.26","price_state":"stated","total_value":208794.0,"total_display":"208,794.00","total_whole":"208,794","shares_owned_after":12546.0,"shares_owned_after_display":"12,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-09","filed_date":"2025-06-11","scope":"insider"},{"id":6558396,"accession":"0001415889-22-011878","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-22-011878","line_url":"/filing/0001415889-22-011878#line-2","is_derivative":false,"issuer_cik":"0001384243","issuer_name":"Kiniksa Pharmaceuticals, Ltd.","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001384243","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21959.0,"shares_display":"21,959","price_per_share":16.15,"price_display":"16.15","price_state":"stated","total_value":354637.85,"total_display":"354,637.85","total_whole":"354,638","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-29","filed_date":"2022-12-01","scope":"insider"},{"id":8569173,"accession":"0001209191-19-052612","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-052612","line_url":"/filing/0001209191-19-052612#line-2","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"HERON THERAPEUTICS, INC. /DE/","issuer_ticker":"HRTX","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4571.0,"shares_display":"4,571","price_per_share":17.5,"price_display":"17.50","price_state":"stated","total_value":79992.5,"total_display":"79,992.50","total_whole":"79,993","shares_owned_after":94652.0,"shares_owned_after_display":"94,652","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-03","filed_date":"2019-10-04","scope":"insider"},{"id":6824811,"accession":"0001209191-18-039348","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-039348","line_url":"/filing/0001209191-18-039348#line-3","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"HERON THERAPEUTICS, INC. /DE/","issuer_ticker":"HRTX","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":39.05,"price_display":"39.05","price_state":"stated","total_value":1952500.0,"total_display":"1,952,500.00","total_whole":"1,952,500","shares_owned_after":69600.0,"shares_owned_after_display":"69,600","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-21","filed_date":"2018-06-22","scope":"insider"},{"id":6822912,"accession":"0001209191-18-020736","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-020736","line_url":"/filing/0001209191-18-020736#line-2","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"HERON THERAPEUTICS, INC. /DE/","issuer_ticker":"HRTX","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":29.75,"price_display":"29.75","price_state":"stated","total_value":2975000.0,"total_display":"2,975,000.00","total_whole":"2,975,000","shares_owned_after":67993.0,"shares_owned_after_display":"67,993","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-19","filed_date":"2018-03-19","scope":"insider"},{"id":6593072,"accession":"0000899243-18-007825","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-007825","line_url":"/filing/0000899243-18-007825#line-2","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"HERON THERAPEUTICS, INC. /DE/","issuer_ticker":"HRTX","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":24.75,"price_display":"24.75","price_state":"stated","total_value":2475000.0,"total_display":"2,475,000.00","total_whole":"2,475,000","shares_owned_after":67993.0,"shares_owned_after_display":"67,993","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-14","filed_date":"2018-03-16","scope":"insider"},{"id":8247498,"accession":"0001209191-15-022537","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-022537","line_url":"/filing/0001209191-15-022537#line-1","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"HERON THERAPEUTICS, INC. /DE/","issuer_ticker":"HRTX","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":13.0727,"price_display":"13.07","price_state":"stated","total_value":130727.0,"total_display":"130,727.00","total_whole":"130,727","shares_owned_after":42868.0,"shares_owned_after_display":"42,868","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-02","filed_date":"2015-03-04","scope":"insider"},{"id":7014977,"accession":"0001209191-14-043928","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-043928","line_url":"/filing/0001209191-14-043928#line-1","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"HERON THERAPEUTICS, INC. /DE/","issuer_ticker":"HRTX","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":11.75,"price_display":"11.75","price_state":"stated","total_value":117500.0,"total_display":"117,500.00","total_whole":"117,500","shares_owned_after":61855.0,"shares_owned_after_display":"61,855","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-25","filed_date":"2014-06-26","scope":"insider"},{"id":6791396,"accession":"0001246360-14-003051","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-14-003051","line_url":"/filing/0001246360-14-003051#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1375.0,"shares_display":"1,375","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":137500.0,"total_display":"137,500.00","total_whole":"137,500","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-20","filed_date":"2014-06-24","scope":"insider"},{"id":6536222,"accession":"0001246360-14-003019","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-14-003019","line_url":"/filing/0001246360-14-003019#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":90000.0,"total_display":"90,000.00","total_whole":"90,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-17","filed_date":"2014-06-19","scope":"insider"},{"id":6975639,"accession":"0001246360-14-002942","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001246360-14-002942","line_url":"/filing/0001246360-14-002942#line-2","is_derivative":false,"issuer_cik":"0000911326","issuer_name":"SYNAGEVA BIOPHARMA CORP","issuer_ticker":"GEVA","issuer_name_source":null,"issuer_url":"/issuer/0000911326","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":83.31,"price_display":"83.31","price_state":"stated","total_value":83310.0,"total_display":"83,310.00","total_whole":"83,310","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-12","filed_date":"2014-06-16","scope":"insider"},{"id":4956443,"accession":"0000904454-13-001236","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000904454-13-001236","line_url":"/filing/0000904454-13-001236#line-1","is_derivative":false,"issuer_cik":"0000818033","issuer_name":"AP PHARMA INC /DE/","issuer_ticker":"APPA","issuer_name_source":null,"issuer_url":"/issuer/0000818033","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":400000.0,"total_display":"400,000.00","total_whole":"400,000","shares_owned_after":1037100.0,"shares_owned_after_display":"1,037,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-20","filed_date":"2013-11-21","scope":"insider"},{"id":8871770,"accession":"0001209191-11-027763","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-11-027763","line_url":"/filing/0001209191-11-027763#line-2","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":27.2038,"price_display":"27.20","price_state":"stated","total_value":544076.0,"total_display":"544,076.00","total_whole":"544,076","shares_owned_after":62202.0,"shares_owned_after_display":"62,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-05-09","filed_date":"2011-05-11","scope":"insider"},{"id":9007156,"accession":"0001209191-11-008239","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-11-008239","line_url":"/filing/0001209191-11-008239#line-2","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":26.7676,"price_display":"26.77","price_state":"stated","total_value":535352.0,"total_display":"535,352.00","total_whole":"535,352","shares_owned_after":47202.0,"shares_owned_after_display":"47,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-02-07","filed_date":"2011-02-09","scope":"insider"},{"id":7514307,"accession":"0001209191-10-059766","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-10-059766","line_url":"/filing/0001209191-10-059766#line-3","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":21.9196,"price_display":"21.92","price_state":"stated","total_value":438392.0,"total_display":"438,392.00","total_whole":"438,392","shares_owned_after":37202.0,"shares_owned_after_display":"37,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-12-08","filed_date":"2010-12-10","scope":"insider"},{"id":7574985,"accession":"0001209191-10-041997","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-10-041997","line_url":"/filing/0001209191-10-041997#line-2","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":20.2134,"price_display":"20.21","price_state":"stated","total_value":404268.0,"total_display":"404,268.00","total_whole":"404,268","shares_owned_after":41858.0,"shares_owned_after_display":"41,858","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-08-09","filed_date":"2010-08-10","scope":"insider"},{"id":7693101,"accession":"0001209191-10-026221","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-10-026221","line_url":"/filing/0001209191-10-026221","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":21.20248032,"price_display":"21.20","price_state":"stated","total_value":530062.008,"total_display":"530,062.01","total_whole":"530,062","shares_owned_after":43919.0,"shares_owned_after_display":"43,919","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-05-07","filed_date":"2010-05-07","scope":"insider","n_lines":2},{"id":7544512,"accession":"0001209191-10-008130","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-10-008130","line_url":"/filing/0001209191-10-008130#line-3","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":14.5707,"price_display":"14.57","price_state":"stated","total_value":364267.5,"total_display":"364,267.50","total_whole":"364,268","shares_owned_after":21515.0,"shares_owned_after_display":"21,515","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-02-08","filed_date":"2010-02-10","scope":"insider"},{"id":5770278,"accession":"0001209191-09-056720","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-056720","line_url":"/filing/0001209191-09-056720#line-2","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":14.4797,"price_display":"14.48","price_state":"stated","total_value":361992.5,"total_display":"361,992.50","total_whole":"361,993","shares_owned_after":37015.0,"shares_owned_after_display":"37,015","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-09","filed_date":"2009-12-11","scope":"insider"},{"id":5929286,"accession":"0001209191-09-040612","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-040612","line_url":"/filing/0001209191-09-040612#line-2","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":19.3252,"price_display":"19.33","price_state":"stated","total_value":483130.0,"total_display":"483,130.00","total_whole":"483,130","shares_owned_after":16511.0,"shares_owned_after_display":"16,511","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-08-11","filed_date":"2009-08-13","scope":"insider"},{"id":5966152,"accession":"0001209191-09-028208","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-09-028208","line_url":"/filing/0001209191-09-028208","is_derivative":false,"issuer_cik":"0001103390","issuer_name":"Ardea Biosciences, Inc./DE","issuer_ticker":"RDEA","issuer_name_source":null,"issuer_url":"/issuer/0001103390","owner_cik":"0001384243","owner_name":"Quart Barry D","owner_display_name":"Quart Barry D","owner_url":"/insider/0001384243","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":15.38730328,"price_display":"15.39","price_state":"stated","total_value":384682.582,"total_display":"384,682.58","total_whole":"384,683","shares_owned_after":44773.0,"shares_owned_after_display":"44,773","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-05-19","filed_date":"2009-05-21","scope":"insider","n_lines":7}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":38,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":35,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":38},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001730430","name":"Kiniksa Pharmaceuticals International, plc","url":"/issuer/0001730430","role":"Director","n_filings":7,"first_seen":"2022-12-01","last_seen":"2026-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0000818033","name":"HERON THERAPEUTICS, INC. /DE/","url":"/issuer/0000818033","role":"Director, Officer (Chief Executive Officer)","n_filings":7,"first_seen":"2013-11-21","last_seen":"2019-10-04"},{"type":"issuer","type_label":"ISSUER","cik":"0000911326","name":"SYNAGEVA BIOPHARMA CORP","url":"/issuer/0000911326","role":"Director","n_filings":3,"first_seen":"2014-06-16","last_seen":"2014-06-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001103390","name":"Ardea Biosciences, Inc./DE","url":"/issuer/0001103390","role":"Director, Officer (President and CEO)","n_filings":9,"first_seen":"2009-05-21","last_seen":"2011-05-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001384243","retrieved_at":"2026-08-26T14:41:48+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}